NON-BIOLOGICAL FACTORS DRIVE FRONTLINE FIXED - DURATION TREATMENT SELECTION IN CLL: REAL-WORLD EVIDENCE FROM THE GIMEMA CLL2121 STUDY (SIE 2026) - Oct 6, 2026 - Abstract #DP028; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; "However, the availability of fully oral fixed-duration regimens, such as ibrutinib–venetoclax (IV), and intravenous anti-CD20–based combinations, such as venetoclax–obinutuzumab (VO), may introduce additional de- terminants of choice. Despite comparable biological profiles, treat- ment selection between IV and VO is largely driven by non- biological and logistics factors. The rapid shift to IV after its market availability supports a dynamic decision-making mod- el in frontline CLL, where biological assessment defines eli- gibility for fixed-duration therapy, while access, logistics, and perceived safety drive real-world choice."
Clinical • HEOR • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • IGH • TP53
|
|
A. Tomasso1,2; L. Scarfò3,4; I. Innocenti1; A. Frustaci5; C. Vitale6; A. Bavieri7; A. Sanna8; E. A. Martino9; R. Marasca10; R. Moia11; M. Motta12; E. Sant'Antonio3; M. Coscia13; I. Scortechini14; A. Visentin15; A. Galitzia16; P. Sportoletti17; S. Pepe18; A. Ibatici19; L. De Padua20; A. Fresa21; J. Olivieri22; A. Arcari23; A. Genua24; A. Zappaterra5; F. Perutelli6; L. Arletti7; C. M. Rapolla25; L. Stirparo1,2; T. Quaranta2; F. Autore1; V. Arena26; F. Paoloni26; A. Piciocchi26; G. M. Rigolin27; A. Cuneo27; P. Ghia3,4; L. Laurenti1,2
|